Neostigmy combined with atropine for the treatment of Postdural Puncture Headache: a randomized controlled trial.

Neostigmin and atropine in the prevention of Postdural Puncture Headache: a randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037863

Enrollment

Unknown

Registered

2020-09-02

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postdural Puncture Headache

Interventions

Group 1:Neostigmin and atropine, intravenous drip

Group 2:Neostigmin and atropine, intravenous injection

Group 3:normal saline, intravenous injection

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Subjects of full-term pregnancy (37-42 gestational weeks); 2. Parturient with singleton; 3. Subjects of ASA grade I-II; 4. Subjects aged over 18 years old; 5. The subject of unexpected dural puncture.

Exclusion criteria

Exclusion criteria: 1. The patients refused to use neostigmine and atropine; 2. Patients who are known to be allergic to lidocaine, ropivacaine and other local anesthetic drugs or other drugs in this study; 3. Patients with abnormal platelet or coagulation function, liver function or renal function; 4. Patients with previous cardiovascular, respiratory, neurological or psychiatric diseases; 5. Patients with skin and soft tissue infection at the puncture site, or trauma, fracture, operation history, lumbar disc herniation at the puncture site; 6. Patients with cephalopelvic disproportion, macrosomia, etc.; 7. Subjects considered unsuitable for clinical trials.

Design outcomes

Primary

Measure	Time frame
incidence of PDPH;	—

Countries

China

Contacts

Public ContactShengxing Zheng

Wenzhou Medical College

zsx0106014@163.com+86 13858899373

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026